A comprehensive drug screen identifies the most potent therapeutic combinations in T-PLL. Different combinations of MDM2 antagonists, HDAC inhibitors, BCL-2 inhibitors, and purine analogues exert a potent cytotoxic effect in T-PLL with the potential to improve patients’ outcomes.

A comprehensive drug screen identifies the most potent therapeutic combinations in T-PLL. Different combinations of MDM2 antagonists, HDAC inhibitors, BCL-2 inhibitors, and purine analogues exert a potent cytotoxic effect in T-PLL with the potential to improve patients’ outcomes.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal